Advances in postoperative adjuvant therapy for primary liver cancer

Table 1 Clinical studies of postoperative adjuvant therapy under investigation for hepatocellular carcinoma

NCT	Phase	Treatment option	Patient population	Expected group entry	Primary endpoint	Status
NCT03383458 (CheckMate 9DX)	III	Nivolumab	High-risk recurrent HCC after radical resection/ablation	530	RFS	Follow-up
NCT04233840	I/II	Nivolumab ± P1101	Post-radical resection of HBV-related HCC	72	Phase I: DLT, phase II: RFS	Recruiting
NCT03867084 (KEYNOTE-937)	III	Pembrolizumab	Imaging CR after surgical resection/local ablation	950	RFS, OS	Recruiting
NCT04639180	III	Camrelizumab + apatinib	High-risk recurrent HCC after surgical resection or ablation	674	RFS	Recruiting
NCT03839550	II	Camrelizumab + apatinib	High-risk recurrent HCC after radical surgery	200	RFS	Not yet recruited
NCT04102098 (IMbrave050)	III	Atezolizumab + bevacizumab	High-risk recurrent HCC after surgical resection/ablation	662	RFS	Recruiting
NCT04649489	-	Atezolizumab + bevacizumab	Post hepatectomy with portal vein carcinoma thrombosis HCC	198	TTF	Not yet recruited
NCT03847428 (EMERALD-2)	III	Durvalumab + bevacizumab	High-risk recurrent HCC after radical resection/ablation	888	RFS	Recruiting

CR: Complete response; DLT: Dose-limiting toxicity; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; OS: Overall survival; RFS: Recurrence-free survival; TTF: Time to treatment failure.